REGULATORY
Cost-Effective Assessments “Not Appropriate” for Everything: MED Director Suzuki
Speaking about the cautionary remarks heard repeatedly on the implementation of evaluations using cost-effective assessments during the first meeting of the Central Social Insurance Medical Council’s (CSIMC) Expert Subcommittee on Cost-Effective Assessments, Yasuhiro Suzuki, director of the Health Insurance Bureau’s…
To read the full story
REGULATORY
- Japan Approves AbbVie’s Aquipta, Novo’s IcoSema, Pfizer’s Tukysa, and More
February 20, 2026
- Health Minister Signals Early March Approval for iPSC Products
February 20, 2026
- Takaichi Urges Public-Private Investment Push in Drug Discovery
February 20, 2026
- Two iPSC-Derived Products Now in Line for Conditional Approval
February 20, 2026
- PM Takaichi Keeps Cabinet Intact after Lower House Vote
February 18, 2026
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…





